A Case of Slowly Progressive Type 1 Diabetes Mellitus (SPIDDM, Probable) Successfully Managed With Oral Semaglutide for Glycemic Control and Weight Management Accompanied by Changes in Eating Behavior.

Hirai T, Kitada M, Endo K, Hayashi K, Suzuki T

Cureus7 Nov 2025Cited by 1 (Europe PMC)

PMID41367443PMCIDPMC12682503DOI10.7759/cureus.96335PepBankPUB-41367443

Summary

The role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) as a standard treatment for slowly progressive type 1 diabetes mellitus (SPIDDM), a condition akin to latent autoimmune diabetes in adults (LADA) or latent autoimmune diabetes in the young (LADY), and a term primarily used in Japan, remains to be fully established. However, these agents show potential as a therapeutic option. We report a case of a 23-year-old Japanese woman who had SPIDDM (probable) since the age of 19 and had poor glycemic and weight control despite treatment with insulin, dapagliflozin, and metformin. Following the initiation of oral semaglutide (a GLP-1 RA), significant improvements in glycemic levels and weight were observed, enabling the discontinuation of insulin. Notably, beneficial changes in her eating behavior were also evident after oral semaglutide administration. This case suggests that GLP-1 RAs are a beneficial therapeutic option for glucose and weight management in patients with SPIDDM (probable), particularly when accompanied by favorable alterations in eating behavior, thus warranting further investigation.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanCase report or seriesEfficacy outcome
In a woman with slowly progressive type 1 diabetes, oral semaglutide was followed by significant improvement in glycemic levels.
In plain wordsIn one young woman with slowly progressive type 1 diabetes, blood sugar control improved after she started oral semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedGlycemic levels
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Following the initiation of oral semaglutide (a GLP-1 RA), significant improvements in glycemic levels and weight were observed, enabling the discontinuation of insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a case of a 23-year-old Japanese woman who had SPIDDM (probable) since the age of 19 and had poor glycemic and weight control despite treatment with insulin, dapagliflozin, and metformin.
Show in the study text Report a problemFND-4136744301
02HumanCase report or seriesEfficacy outcome
In a woman with slowly progressive type 1 diabetes, oral semaglutide was followed by significant improvement in weight.
In plain wordsIn one young woman with slowly progressive type 1 diabetes, weight improved after she started oral semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedBody weight
Study
n = 1
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Following the initiation of oral semaglutide (a GLP-1 RA), significant improvements in glycemic levels and weight were observed, enabling the discontinuation of insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a case of a 23-year-old Japanese woman who had SPIDDM (probable) since the age of 19 and had poor glycemic and weight control despite treatment with insulin, dapagliflozin, and metformin.
Show in the study text Report a problemFND-4136744302
03HumanCase report or seriesEfficacy outcome
In a woman with slowly progressive type 1 diabetes, improvements after oral semaglutide allowed insulin to be discontinued.
In plain wordsIn one young woman with slowly progressive type 1 diabetes, she could stop insulin after starting oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseInsulin discontinuation
Study
n = 1
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Following the initiation of oral semaglutide (a GLP-1 RA), significant improvements in glycemic levels and weight were observed, enabling the discontinuation of insulin.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a case of a 23-year-old Japanese woman who had SPIDDM (probable) since the age of 19 and had poor glycemic and weight control despite treatment with insulin, dapagliflozin, and metformin.
Show in the study text Report a problemFND-4136744303
04HumanCase report or seriesEfficacy outcome
In a woman with slowly progressive type 1 diabetes, beneficial changes in eating behavior were evident after oral semaglutide.
In plain wordsIn one young woman with slowly progressive type 1 diabetes, her eating behavior changed in a helpful way after oral semaglutide.
Peptide
Semaglutide
Outcome
Direction not reportedEating behavior
Study
n = 1
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
Dose not stated · oralAs given in this study (human).
Source sentences
Summary
Notably, beneficial changes in her eating behavior were also evident after oral semaglutide administration.
1 context sentence(design, population, supporting numbers)
Summary · context
We report a case of a 23-year-old Japanese woman who had SPIDDM (probable) since the age of 19 and had poor glycemic and weight control despite treatment with insulin, dapagliflozin, and metformin.
Show in the study text Report a problemFND-4136744304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.